Research Funding


PI: 1R01CA148706 (NIH/NCI)                         Duane D. Miller (Co-I: 2010-2015; MPI: 2016-2026)          

“Targeting the colchicine site in tubulin for cancer therapy”.

PI:1R01CA240447-01A1 (NIH/NCI)                Muxiang Zhou (MPI)        7/2020-6/2025

“Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer”.

PI: 1R01CA193609-01A1 (NIH/NCI)              5/2016-4/2022

“Selective targeting survivin for cancer therapy”.

PI: BC190092                    Tiffany Seagroves (Partner PI)                    3/2020-2/2023

DoD Breast Cancer Research Program

Total budget: $2,269,056 for the duration of 3 years

W81XWH2010011: Li’s part of the project  $1,271,866

W81XWH2010019: Seagroves’ part of the project   $997,190

“Discovery of orally bioavailable tubulin inhibitors to overcome taxane resistance in metastatic breast cancer”

PI: Oxnard Foundation                   7/2019-6/2022

This foundation grant is to support research in the Li lab to develop a new small molecule compound as potentially more effective treatments for pancreatic cancer.

PI: Sponsored Research Agreement #1      7/2019-6/2022

Private Industry for a cancer drug development.

PI: Sponsored Research Agreement #2      Duane Miller (MPI)            1/2020-1/2022

Private Industry for a cancer drug development.

Co-I: 1R24EY029950-01A1 (NIH/NEI)           Monica Jablonski (PI)      3/2020-2/2025

“Novel Extended Release Glaucoma Therapy for Once Daily Dosing”

MPI: R43CA257324-01 (NIH/NCI)          Zhongzhi Wu (NIH contact PI)                     9/2020-8/2022

“Feasibility study of developing SEAK-114 for the treatment of pediatric cancers”

Role: MPI, Founder and owner of the awardee company: SEAK Therapeutics LLC.

Active Internal Funding and Completed Funding:

Please see the relevant sections in the CV.